Rose McNulty

FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.

The Community Oncology Alliance's request includes declarations from community oncology practices detailing the anticipated ramifications should the Most Favored Nation rule become operative.

A new study validates the application of duplex sequencing in detecting mutations caused by chemical carcinogens.

Bradley Monk, MD, FACOG, FACS, clinician at Arizona Oncology, professor at the University of Arizona and Creighton University in Phoenix, discusses the reimbursement of PARP inhibitors in ovarian cancer.

NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.

Panelists at Patient-Centered Oncology Care® 2020 discussed practical methods and the potential benefits of utilizing chronic care management (CCM) billing and telehealth in oncology.

Pharmacy benefit managers (PBMs), once just administrators created to ease claims processing, have grown to a position of power that comes with conflicts of interest aplenty, said a panel at Patient-Centered Oncology Care® 2020.

Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.

Kashyap Patel, MD, associate editor of Evidence-Based Oncology, a publication of The American Journal of Managed Care, will serve a 1-year term beginning in January.

Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.

A combination of pembrolizumab with bevacizumab and cyclophosphamide showed clinical activity and tolerability in patients with recurrent ovarian cancer, a small study found.

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments.

Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer.

A spotlight poster discussion at SABCS highlighted topics in genomic testing, potentially game-changing therapies, and predictive biomarkers in HR-positive breast cancer.

Poster presentations at the San Antonio Breast Cancer Symposium demonstrated the clinical relevance and efficacy of oral paclitaxel plus encequidar in the treatment of metastatic breast cancer.

Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.

City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.

A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.

The American Society of Clinical Oncology calls on government bodies and the health care community to guide the cancer community’s post-pandemic recovery.

Data presented at the 62nd Annual ASH Meeting demonstrated the clinical utility of Adaptive Biotechnologies’ clonoSEQ next-generation sequencing to detect MRD in multiple myeloma patients.

New findings in Journal of the National Cancer Institute contradict previous research indicating that assisted reproductive technology might lead to an increased risk of ovarian cancer.

Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.

A new study published in JAMA Network Open found that the rate of cancer in adolescents and young adults increased by nearly 30% from 1973 to 2015.

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses challenges to progress in getting FDA approval for PARP inhibitors in prostate cancer.

An oncolytic virus called CF33 developed at City of Hope shows potential for colon cancer treatment and tumor regrowth immunity in mouse models.

Frederick Schnell, MD, FACP, medical director of COA, discusses how employers' concerns with cancer care coverage can be addressed without compromising quality.

Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.

Randall Oyer, MD, president of the Association of Community Cancer Centers, discusses the ACCC and American Society of Clinical Oncology's initiative to make clinical trials more inclusive.

City of Hope's Dr. Tanya Siddiqi offers an update on a new chimeric antigen receptor (CAR) T-cell therapy awaiting approval from the FDA.

A first-of-its-kind partnership between OneOncology and Genentech aims to bring more personalized cancer care to community oncology centers nationwide.